Literature DB >> 20068396

Raxibacumab.

Sohini Mazumdar1.   

Abstract

Raxibacumab (ABthrax) is a human IgG1 monoclonal antibody against Bacillus anthracis protective antigen. HGS is currently providing stockpiles of the agent to the US government for use in the prevention and treatment of inhalation anthrax. As of May 2009, the candidate was undergoing review by the US Food and Drug Administration. The availability of bioterrorism countermeasures has become more important since the September 2001 anthrax attacks, and development of raxibacumab is a significant advance in this area.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 20068396      PMCID： PMC2791309          DOI： 10.4161/mabs.1.6.10195

Source DB:  PubMed          Journal:  MAbs        ISSN： 1942-0862            Impact factor:   5.857


  9 in total

1.  Protecting against future shock--inhalational anthrax.

Authors:  Gary J Nabel
Journal:  N Engl J Med       Date:  2009-07-09       Impact factor: 91.245

Review 2.  Anthrax as a biological weapon, 2002: updated recommendations for management.

Authors:  Thomas V Inglesby; Tara O'Toole; Donald A Henderson; John G Bartlett; Michael S Ascher; Edward Eitzen; Arthur M Friedlander; Julie Gerberding; Jerome Hauer; James Hughes; Joseph McDade; Michael T Osterholm; Gerald Parker; Trish M Perl; Philip K Russell; Kevin Tonat
Journal:  JAMA       Date:  2002-05-01       Impact factor: 56.272

3.  A phase 1 study of PAmAb, a fully human monoclonal antibody against Bacillus anthracis protective antigen, in healthy volunteers.

Authors:  G Mani Subramanian; Patrick W Cronin; Gerald Poley; Andrea Weinstein; Susan M Stoughton; John Zhong; Ying Ou; Jonathan F Zmuda; Blaire L Osborn; William W Freimuth
Journal:  Clin Infect Dis       Date:  2005-05-24       Impact factor: 9.079

4.  Late treatment with a protective antigen-directed monoclonal antibody improves hemodynamic function and survival in a lethal toxin-infused rat model of anthrax sepsis.

Authors:  Xizhong Cui; Yan Li; Mahtab Moayeri; Gil H Choi; G M Subramanian; Xuemei Li; Michael Haley; Yvonne Fitz; Jing Feng; Steven M Banks; Stephen H Leppla; Peter Q Eichacker
Journal:  J Infect Dis       Date:  2004-12-22       Impact factor: 5.226

5.  New drug and biological drug products; evidence needed to demonstrate effectiveness of new drugs when human efficacy studies are not ethical or feasible. Final rule.

Authors: 
Journal:  Fed Regist       Date:  2002-05-31

Review 6.  Anti-toxin antibodies in prophylaxis and treatment of inhalation anthrax.

Authors:  Anette Schneemann; Marianne Manchester
Journal:  Future Microbiol       Date:  2009-02       Impact factor: 3.165

7.  Raxibacumab for the treatment of inhalational anthrax.

Authors:  Thi-Sau Migone; G Mani Subramanian; John Zhong; Letha M Healey; Al Corey; Matt Devalaraja; Larry Lo; Stephen Ullrich; Janelle Zimmerman; Andrew Chen; Maggie Lewis; Gabriel Meister; Karen Gillum; Daniel Sanford; Jason Mott; Sally D Bolmer
Journal:  N Engl J Med       Date:  2009-07-09       Impact factor: 91.245

8.  Project BioShield: what it is, why it is needed, and its accomplishments so far.

Authors:  Philip K Russell
Journal:  Clin Infect Dis       Date:  2007-07-15       Impact factor: 9.079

Review 9.  Anti-infective monoclonal antibodies: perils and promise of development.

Authors:  Janice M Reichert; Matthew C Dewitz
Journal:  Nat Rev Drug Discov       Date:  2006-03       Impact factor: 84.694
  9 in total
  35 in total

Review 1.  Development of anti-infectives using phage display: biological agents against bacteria, viruses, and parasites.

Authors:  Johnny X Huang; Sharon L Bishop-Hurley; Matthew A Cooper
Journal:  Antimicrob Agents Chemother       Date:  2012-06-04       Impact factor: 5.191

Review 2.  Development trends for human monoclonal antibody therapeutics.

Authors:  Aaron L Nelson; Eugen Dhimolea; Janice M Reichert
Journal:  Nat Rev Drug Discov       Date:  2010-09-03       Impact factor: 84.694

Review 3.  Anthrax lethal and edema toxins in anthrax pathogenesis.

Authors:  Shihui Liu; Mahtab Moayeri; Stephen H Leppla
Journal:  Trends Microbiol       Date:  2014-03-27       Impact factor: 17.079

Review 4.  Drugs derived from phage display: from candidate identification to clinical practice.

Authors:  Andrew E Nixon; Daniel J Sexton; Robert C Ladner
Journal:  MAbs       Date:  2014 Jan-Feb       Impact factor: 5.857

5.  Revisiting the Concept of Targeting Only Bacillus anthracis Toxins as a Treatment for Anthrax.

Authors:  Itai Glinert; Elad Bar-David; Assa Sittner; Shay Weiss; Josef Schlomovitz; Amir Ben-Shmuel; Adva Mechaly; Zeev Altboum; David Kobiler; Haim Levy
Journal:  Antimicrob Agents Chemother       Date:  2016-07-22       Impact factor: 5.191

Review 6.  Antitoxin Treatment of Inhalation Anthrax: A Systematic Review.

Authors:  Eileen Huang; Satish K Pillai; William A Bower; Katherine A Hendricks; Julie T Guarnizo; Jamechia D Hoyle; Susan E Gorman; Anne E Boyer; Conrad P Quinn; Dana Meaney-Delman
Journal:  Health Secur       Date:  2015 Nov-Dec

Review 7.  Phage Display Libraries: From Binders to Targeted Drug Delivery and Human Therapeutics.

Authors:  Mouldy Sioud
Journal:  Mol Biotechnol       Date:  2019-04       Impact factor: 2.695

Review 8.  Anti-bacterial monoclonal antibodies: next generation therapy against superbugs.

Authors:  Hui Wang; Daijie Chen; Huili Lu
Journal:  Appl Microbiol Biotechnol       Date:  2022-06-01       Impact factor: 4.813

9.  Role of Interstitial Fluid Turnover on Target Suppression by Therapeutic Biologics Using a Minimal Physiologically Based Pharmacokinetic Model.

Authors:  Xiaobing Li; William J Jusko; Yanguang Cao
Journal:  J Pharmacol Exp Ther       Date:  2018-07-12       Impact factor: 4.030

Review 10.  Developing Recombinant Antibodies by Phage Display Against Infectious Diseases and Toxins for Diagnostics and Therapy.

Authors:  Kristian Daniel Ralph Roth; Esther Veronika Wenzel; Maximilian Ruschig; Stephan Steinke; Nora Langreder; Philip Alexander Heine; Kai-Thomas Schneider; Rico Ballmann; Viola Fühner; Philipp Kuhn; Thomas Schirrmann; André Frenzel; Stefan Dübel; Maren Schubert; Gustavo Marçal Schmidt Garcia Moreira; Federico Bertoglio; Giulio Russo; Michael Hust
Journal:  Front Cell Infect Microbiol       Date:  2021-07-07       Impact factor: 5.293
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.